2. Academic Validation
  3. Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

  • Cancer Chemother Pharmacol. 2014 Jul;74(1):151-66. doi: 10.1007/s00280-014-2476-y.
Wendi V Rodrigueza 1,  Michael J Woolliscroft,  Abdul-Shukkur Ebrahim,  Robert Forgey,  Patrick J McGovren,  Gerold Endert,  Andreas Wagner,  Danielle Holewa,  Amro Aboukameel,  Richard D Gill,  Charles L Bisgaier,  Richard A Messmann,  Christopher E Whitehead,  Elzbieta Izbicka,  Robert Streeper,  Michael C Wick,  Gabriela Stiegler,  C A Stein,  David Monsma,  Craig Webb,  Mina P Sooch,  Steffen Panzner,  Ramzi Mohammad,  Neal C Goodwin,  Ayad Al-Katib
Affiliations

Affiliation

  • 1 ProNAi Therapeutics, Inc., Plymouth, MI, USA, wrodrigueza@pronai.com.
PMID: 24832107 DOI: 10.1007/s00280-014-2476-y
Abstract

PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to a region upstream of the Bcl-2 gene. Exposure of tumor cells to PNT100 results in suppression of proliferation and cell death by a process called DNA interference. PNT2258 is PNT100 that is encapsulated in protective amphoteric liposomes developed to efficiently encapsulate the PNT100 oligonucleotide, provide enhanced serum stability, optimized pharmacokinetic properties and antitumor activity of the nanoparticle both in vivo and in vitro. PNT2258 demonstrates broad antitumor activity against BCL-2-driven WSU-DLCL2 lymphoma, highly resistant A375 melanoma, PC-3 prostate, and Daudi-Burkitt's lymphoma xenografts. The sequence specificity of PNT100 was demonstrated against three control sequences (scrambled, mismatched, and reverse complement) all encapsulated in a lipid formulation with identical particle characteristics, and control sequences did not demonstrate antiproliferative activity in vivo or in vitro. PNT2258 is currently undergoing clinical testing to evaluate safety and antitumor activity in patients with recurrent or refractory non-Hodgkin's lymphoma and additional studies are planned.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z